加载中
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
最新数据
HK$7.355
−HK$0.185 · -2.45%
盘中时间采用HKT。市场数据可能有所延迟。
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
日内区间
当前HK$7.355
52周区间
当前HK$7.355
盘中时间采用HKT。市场数据可能有所延迟。
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
日内区间
当前HK$7.355
52周区间
当前HK$7.355
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.52亿 CNY | 6.4亿 CNY | 2.19亿 CNY | 1.67亿 CNY | 1.46亿 CNY |
| 销货成本 | 1.25亿 CNY | 6031.6万 CNY | 5523.7万 CNY | 4420.7万 CNY | 302.8万 CNY |
| 毛利 | 4.27亿 CNY | 5.8亿 CNY | 1.64亿 CNY | 1.23亿 CNY | 1.43亿 CNY |
| 研究与开发 | 4.94亿 CNY | 4.04亿 CNY | 4.08亿 CNY | 4.68亿 CNY | 4.81亿 CNY |
| 销售、一般及管理费用 | 8164.97万 CNY | 7510.9万 CNY | 7933.8万 CNY | 8694万 CNY | 7755万 CNY |
| 营业费用 | 5.76亿 CNY | 4.79亿 CNY | 4.87亿 CNY | 5.55亿 CNY | 5.59亿 CNY |
| 利息收入 | 3438.25万 CNY | 4925.5万 CNY | 7404.2万 CNY | 3386.6万 CNY | 2780.7万 CNY |
| 利息支出 | 725.62万 CNY | 992.4万 CNY | 1217.9万 CNY | 1420.6万 CNY | 1318.2万 CNY |
| 折旧和摊销 | 6468.3万 CNY | 7703.1万 CNY | 6911.8万 CNY | 5518.8万 CNY | 4110.2万 CNY |
| 营业利润 | −1.49亿 CNY | 1.01亿 CNY | −3.06亿 CNY | −4.32亿 CNY | −4.16亿 CNY |
| 净利润 | −1.11亿 CNY | 1.66亿 CNY | −2.11亿 CNY | −3.26亿 CNY | −4.12亿 CNY |
公司数据更新于 2026年10月10日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Total International Stock ETFVXUS800.94万0.00%6657亿 USD0.05%US$84.82+0.86%
Vanguard FTSE Emerging Markets ETFVWO763.49万0.00%1685亿 USD0.06%US$59.76+1.12%
iShares Core MSCI Emerging Markets ETFIEMG258.14万0.00%1589.63亿 USD0.09%US$81.40+1.12%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS246.77万0.02%145亿 USD0.06%US$155.12+0.98%
Vanguard Total World Stock ETFVT36.88万0.00%1017亿 USD0.06%US$159.83+0.69%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX31.21万0.05%6.65亿 USD0.65%US$71.64+1.00%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM27.96万0.00%96.67亿 USD0.39%US$40.01+1.07%
iShares MSCI China Small-Cap ETFECNS19.12万0.31%6125.95万 USD0.59%US$27.45+1.72%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares Core MSCI Emerging Markets ETFIEMGVanguard FTSE All-World ex-US Small-Cap ETFVSSVanguard Total World Stock ETFVTState Street SPDR S&P Emerging Markets Small Cap ETFEWXDimensional - Emerging Markets Core Equity 2 ETFDFEMiShares MSCI China Small-Cap ETFECNSAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
